Critical Role of Pathologists in Genomic Era: Correlating Genotype with Phenotype in Hematologic Malignancies.
Hematological malignancies are a heterogeneous group of diseases with diverse presentations and incidence. Major advances in molecular and cell biology have improved our understanding of the pathophysiology of myeloid neoplasms, expanded treatment options, and provided a deeper understanding of how and why individual patients may be at increased risk for development of hematologic malignancies. The recent accumulation of genetic data on the molecular underpinnings of myeloid neoplasms as well as numerous recently approved novel therapies have highlighted areas of controversy in how we currently define and classify myeloid malignancies. Pathologic examination of bone marrow is the definitive diagnostic procedure for hematopoietic disorders, both benign and malignant. For many patients, it is the final step in identifying previously elusive disorders. This talk will focus on presentation and areas of diagnostic confusion among myeloid malignancies.
Please check back for the Q&A.